ABSTRACT
Objective To observe the expression change of embryonic dry related genes in embryonic stem of pancreatic cancer and analyze its significance.Methods Pancreatic cancer cell lines PANC-1 was incubated with with CD24,CD44 antibody incubation,the CD24 + and CD44 +pancreatic cancer stem cells were sorted and pancreatic cancer stem cells' forming speed were observed under a microscope.The differentiation of stem cells were induced by 1640 culture,and the expression of CD24 +and CD44 +were detected by flow cytometry.The expression of embryonic stem cell marker Oct4 and Nano were detected by immunohistochemical and the tolerance difference of Oct4 and Nano cell to chemotherapeutic drugs in vitro were observed and compared by CCK8 method.Results The number of CD24 +and CD44 +isolated from human pancreatic cancer cell lines PANC-1 was 1%~3%.Oct4 and Nano expression in sorted cells were significantly higher than un -sorted cells,and the difference was significant (P<0.05 ). Conclusion CD24 +and CD44 +cells has high drug resistance and other characteristics of pancreatic cancer stem cells,and the expression of embryonic stem-related genes Oct4 and Nano are high pancreatic cancer stem cells.
ABSTRACT
Objective To compare the efficacy and safety of S-1 plus nedaplatin and standard second-line chemotherapy in the treatment of advanced lung adenocarcinoma that failure in the first-line chemotherapy.Methods A total of 95 cases with IIIb-IV stage non-small cell lung adenocarcinoma that failure in the first-line chemotherapy was included in this paper and divided into two groups:group A(n=5 1 )was treated with S-1 combined with nedaplatin chemotherapy;group B(n=44)was treated with pemetrexed or docetaxel single-agent chemotherapy,21 days were a cycle of treatment,and totally 4 cycles of chemotherapy. Results The objective response rates(CRR)in group A and group B were 33.0% and 19.3%respectively(P<0.05),and the difference was significant;the clinical benefit rates(CBR)in two groups were 57. 1% and 40.9% respectively (P <0.05 ),and there was significant difference between two groups. The median perfect forward secrecy(PFS)was 99 days and 40 days respectively,and the difference between two groups was significant(P<0.05 ). The one-year survival rates in groups A and B were 5 1.3% and 33.7%(P<0.05 ),and there was significant difference(P<0.05 ). Logistic multi-factor regression analysis showed that the ORR and CER had no correlation with the gender, age, proportion score (PS )and the first-line chemotherapy selection. Conclusion S-1 plus nedaplatin chemotherapy is better than the standard second-line chemotherapy in the treatment of advanced lung adenocarcinoma that failure in the first-line chemotherapy,with the advantage of good tolerance,and it can provide a new choice for the treatment of advanced non-small cell lung adenocarcinoma.
ABSTRACT
Objective To assess the efficacy and toxicity of topoteean hydllochloride plus carbo-platin(TC)versus etoposide plus carboplatin(CE)in patients for previously untreated small cell lung cancer (SCLC).Methods Sixty-nine patients with previously untreated SCLC,TC group(34 eases)were treated with topotecan 1 mg/m2 from day 1 to day 5 and carboplatin 300 mg/m2on day 1.CE group(35 cases)were treated with etoposide 100 mg/d from day 1 to day 5 and carboplatin 300 mg/m2 on day 1.Treatment was repeated every 3 weeks.The efficacy and toxicity were ev Mumed in patients who received two cvcles of chemotherapy.ResMN The total effective rate Was 76.5%in TC group and 71.4%in CE group(P＞0.05). The progression-free survival interval was 4.1 months in TC group and 2.6 months in CE group(P＜0.05). There was no significant difference in the most common toxieities between two groups(P＞0.05).Conclusion Compared with etoposide plus carboplatin,topotecan plus carboplatin has similar total effective rate,and in- different toxieities,and the longer progression-free survival interval,so it is a safe and effective first-line treatment for SCLC.
